What drove SKIN.SW stock higher in the pre-market move?

The pre-market rise to **CHF35.70** was driven by above-average volume (**2,756.00**) and trader interest in Cassiopea’s clinical pipeline. Without a firm press release, the move likely reflects speculative accumulation ahead of potential clinical or regulatory news.

What are the key valuation metrics for SKIN.SW stock?

Key metrics: EPS **-1.27**, trailing PE around **-28.13**, book value per share **1.50**, price-to-book **25.50**, 50-day avg price **34.37**, 200-day avg price **37.22**. These reflect a clinical-stage biotech with negative earnings.

How does Meyka AI view SKIN.SW stock near term?

Meyka AI rates SKIN.SW **58.67/100 (C+, HOLD)** and projects a **CHF42.50** 12-month baseline target (+**19.05%**) and a downside of **CHF25.50** (-**28.57%**). Forecasts are model-based projections and not guarantees.

CH Stocks

Pre-market 16 Jan 2026: SKIN.SW Cassiopea (SIX) +9.85% to CHF35.70: targets

ByHuzaifa Zahoor January 16, 2026January 16, 2026

The SKIN.SW stock jumps ahead of the Swiss open after a high-volume move that lifted the price to CHF35.70 on 16 Jan 2026. The pre-market surge of 9.85% came with Volume 2,756.00, above the average of 1,818.00, flagging strong trader interest in Cassiopea S.p.A. (SIX). This article examines the drivers, financial ratios, technical context, and near-term analyst-style targets for investors tracking biotech picks in Switzerland.